CoQ10 is a popular supplement. However like all supplements you have to be very careful because if you do not know the quality of CoQ10 you buy, most likely you’ll be getting Chinese CoQ10, which is NOT the best quality. Instead you want to look for branded ingredients, and in this case you Kaneka q10. This company makes the ONLY CoQ10 supplement from the U.S. The company is called Kaneka.
Here is the brand I recommend buying…Nutrigold CoQ10 Gold (High Absorption) (Clinically-proven KanekaQ10), 100 mg, 120 softgels
Kaneka q10 benefits
For over 30 years Kaneka q10 has made a commitment to quality in making this supplement. They are the industry leaders of Co10 supplementation. Here are the reasons why:
- Kaneka Q10 does not contain any impurities that are synthetically added, unlike most generic version of CoQ10. It is the only yeast-fermented CoQ10 available.
- Kaneka Q10 is the only CoQ10 ingredient made in the United States of America.
- Kaneka Q10 has been used in clinical trials over the past thirty years.
- Kaneka Q10 has Self-Affirmed GRAS status (“generally recognized as safe”) for use in supplements.
- Kaneka Q10 is made under GMP regulations which the FDA looks to see when dietary supplements are made.
- Kaneka Q10 is GMO-free, allergen-free and Kosher certified.
There are several benefits to using with CoQ10. Because it is vital for the essential production of cellular energy, CoQ10 supports stamina and helps the body’s state of health. As a strong antioxidant, it also stops lipid peroxyl radicals production, powers the immune system and fosters resistance to disease. Over the last thirty years, hundreds of studies have been conducted and published on CoQ10 advantages for maintaining good health and beneficial aging.
Study: Supplementation with the reduced form of coenzyme Q10 decelerates phenotypic characteristics of senescence and induces a peroxisome proliferatoractivated receptor-alpha gene expression signature in SAMP1 mice.
Journal: Mol Nutr Food Res. 2010 Jun;54(6):805-15.
Authors: Schmelzer C, Kubo H, Mori M, Sawashita J, Kitano M, Hosoe K, Boomgaarden I, Doring F, Higuchi K.
Department: Institute of Human Nutrition and Food Science, Molecular Prevention, Christian-Albrechts-University of Kiel, Heinrich-Hecht-Platz 10, Kiel, Germany.
Summary/comments: In this study, the researchers conducted broad genome expression profiling in various tissues (liver, kidney, heart and brain) of SAMP1 mice supplemented with Kaneka Ubiquinol or Kaneka Q10 (ubiquinone). The scientists detected the presence of redox-sensitive genes, specifically ubiquinol-dependent gene networks that are involved in inflammation and lipid metabolism. These ubiquinol sensitive genes involved in cholesterol and lipid metabolism were not effected by ubiquinone. The research also indicated that, in comparison to ubiquinone, Kaneka Ubiquinol supplementation was more effective at increasing total CoQ10 levels in the liver.
Study: Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.
Journal: J Neurochem. 2008 Mar;104(6):1613-21. Epub 2007 Oct 31.
Authors: Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, Wille EJ, Beal MF.
Summary/comments: Beal offered his groupʼs most recent findings on mitochondrial dysfunction and neurodegenerative diseases, specifically involving animal models of Parkinsonʼs and Huntingtonʼs disease to compare Ubiquinol and conventional CoQ10 (ubiquinone). In one of the animal models, they utilized a neurotoxin called MPTP, which induces effects in the brain designed to be analogous to clinical and biochemical changes seen in patients with Parkinsonʼs disease. The rodents treated with CoQ10 (both ubiquinone and ubiquinol forms) had significantly less formation of alpha synuclein aggregates, which is a major pathological hallmark found in Parkinsonʼs disease patients. Additionally, the scientists noted that the Ubiquinol form resulted in higher plasma levels and exerted a greater neuroprotective effect against the damaging effect of MPTP.
Antioxidants & Aging
Study: Renal preservation effect of Kaneka Ubiquinol, the reduced form of coenzyme Q10.
Journal: Clinical and Experimental Nephrology
Authors: Ishikawa A, Kawarazaki H, Ando K, Fujita M, Fujita T, Homma Y
Summary/comments: Researchers from the University of Tokyo have been examining the role of antioxidants in Chronic Kidney Disease. As a preliminary study, an animal model of chronic kidney disease was developed. Three experimental groups were created: a control group, a high salt diet group, and a high salt diet plus Ubiquinol group. In comparison to the control group, the high salt diet increased oxidative stress (measured by the generation of superoxide anion in kidney tissue), increased hypertension, and induced albuminuria. However, the high salt diet plus Ubiquinol group exhibited results indicating significant renoprotection by ubiquinol, including decreased generation of superoxide anion (antioxidant effect), decreased urinary albumin, and amelioration of hypertension. This study marks the first experimental research with the antioxidant Ubiquinol in an animal model of chronic kidney disease.
Study: Oxidative burden in prediabetic and diabetic individuals: evidence from plasma coenzyme Q10
Journal: Diabetic Medicine. 2006, 23: 1344-1349
Authors: Lim SC, Tan HH, Goh SK, Subramaniam T, Sum CF, Tan IK, Lee BL, Ong CN
Summary/comments: Singaporean researchers demonstrated that ubiquinol ratios are low in diabetics, however the extent of ubiquinol loss is very severe: Diabetics exhibited approximately 75 percent less ubiquinol as opposed to control (nondiabetic) subjects (chart below). These diabetics were defined by a fasting plasma glucose of ≥ 6.9 mmol/L (blood glucose of ≥ 124 mg/dL). This research demonstrates that the diabeticʼs oxidative stress may cause the conversion of ubiquinol to ubiquinone.
|Blood Glucose||≤ 99 mg/dL||101 – 124 mg/dL||≥ 124 mg/dL|
|Ubiquinol ratio (%) Male||93 ± 6||43 ± 25||24 ± 11|
|Ubiquinol ratio (%) Female||95 ± 6||41 ± 15||29 ± 16|
Study: Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with Trisomy 21
Journal: Pediatr Neurol. 2007 Dec;37(6):398-403
Authors: Miles MV, Patterson BJ, Chalfonte-Evans ML, Horn PS, Hicke FJ, Schapiro MB, Steele PE, Tang PH, Hotze SL
Summary/comments: This is the first study to indicate a pro-oxidant state in plasma of children with trisomy 21, as assessed by ubiquinol-10: total coenzyme Q10 ratio. The scientists found the redox status of coenzyme Q10 in children with trisomy 21 is significantly altered compared with that of healthy children. In addition, after 3 months of supplementation with Ubiquinol, the antioxidant:oxidant imbalance was positively affected in most of these children. Though this did not prove a clinical effect, the results provide a foundation for further research.
Study: Redox status of coenzyme Q10 is associated with chronological age.
Journal: J Am Geriatr Soc. 2007 Jul;55(7):1141-2.
Authors: Wada H, Goto H, Hagiwara S, Yamamoto Y.
Summary/comments: Research has continued to uncover the association between oxidative stress and aging, and recent work done at Kyorin University in Japan demonstrates that ubiquinol is involved. The blood levels of both forms of CoQ10 (ubiquinone and ubiquinol) in subjects in different ages was examined. They found that aged subjects not only have reduced CoQ10 biosynthesis, but also their ability to convert ubiquinone to ubiquinol is also diminished.
Study: Reduced coenzyme Q10 supplementation decelerates senescence in SAMP1 mice.
Journal: Experimental Gerontology 41 (2006) 130–140
Authors: Yan J, Fujii K, Yao J, Kishida H, Hosoe K, Sawashita J, Takeda T, Mori M, Higuchi K
Summary/comments: Scientists from Shinshu University (Department of Aging Biology) investigated the effects of Ubiquinol on a senescence-accelerated mouse strain called SAMP1. Ubiquinol improved the behavior and appearance of the SAMP1 mice and delayed senescence during middle age.